Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Mol Neurobiol ; 56(11): 7267-7283, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31016475

RESUMEN

Identification of molecular mechanisms underlying early-stage Alzheimer's disease (AD) is important for the development of new therapies against and diagnosis of AD. In this study, gas chromatography time-of-flight mass spectrometry (GC-TOF-MS)-based metabolomics approach was employed to investigate the metabolic profiles in plasma and brain tissues harvested from 5-month-old APP/PS1 transgenic mice and their wildtype counterparts. Since different brain regions were expected to have their own distinct metabolic signals, four different brain regions, namely cortex, hippocampus, midbrain and cerebellum tissues, were dissected and had their metabolic profiles studied separately. Biochemical assays were also performed on plasma and brain cortex tissue of transgenic mice and wildtype mice, with a focus on mitochondrial health. Amyloid precursor protein and amyloid-ß levels in plasma, brain cortex tissue and mitochondria fractions isolated from brain cortex were measured to assess the amyloid pathology. Our findings include the observation of extensive metabolic alterations in cortex and cerebellum of APP/PS1 mice, but not in their hippocampus, midbrain and plasma. The major pathways affected in cortex and cerebellum of APP/PS1 mice were closely related to impaired energy metabolism and perturbation of amino acid metabolism in these mice. APP/PS1 mice also exhibited higher amyloid-ß40 and amyloid-ß42 in their cortex, accumulation of mitochondria APP in their cortex, and presented an altered oxidative state in their brain. Treatment with the peroxisome proliferator-activated receptor gamma (PPARγ) agonist pioglitazone (PIO) successfully restored the energy metabolism, lowered amyloid-ß levels and afforded the APP/PS1 mice a better antioxidative capacity in their cortex.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Precursor de Proteína beta-Amiloide/metabolismo , Cerebelo/metabolismo , Corteza Cerebral/metabolismo , PPAR gamma/agonistas , Pioglitazona/uso terapéutico , Presenilina-1/metabolismo , Enfermedad de Alzheimer/sangre , Precursor de Proteína beta-Amiloide/sangre , Animales , Catalasa/metabolismo , Citrato (si)-Sintasa/metabolismo , Análisis Discriminante , Modelos Animales de Enfermedad , Femenino , Hipocampo/metabolismo , L-Lactato Deshidrogenasa/metabolismo , Masculino , Metabolómica , Ratones Transgénicos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Pioglitazona/farmacología , Análisis de Componente Principal , Superóxido Dismutasa/metabolismo
2.
Sci Rep ; 5: 9000, 2015 Mar 11.
Artículo en Inglés | MEDLINE | ID: mdl-25760794

RESUMEN

Pioglitazone is currently undergoing clinical trials for treatment of Alzheimer's disease (AD). However, poor brain penetration remains an obstacle to development of the drug for such intended clinical uses. In this study, we demonstrate that the inhibition of P-glycoprotein (P-gp) significantly increases brain penetration of pioglitazone, whereas inhibition of breast cancer resistance protein (BCRP) has little effect. We also investigate the stereoselectivity of pioglitazone uptake in the brain. When mice were dosed with racemic pioglitazone, the concentration of (+)-pioglitazone was 46.6% higher than that of (-)-pioglitazone in brain tissue and 67.7% lower than that of (-)-pioglitazone in plasma. Dosing mice with pure (+)-pioglitazone led to a 76% increase in brain exposure levels compared to those from an equivalent dose of racemic pioglitazone. Pure (+)-pioglitazone was also shown to have comparable amyloid-lowering capabilities to the racemic pioglitazone in an in vitro AD model. These results suggest that P-gp may act as a stereoselective barrier to prevent pioglitazone entry into the brain. Dosing with (+)-pioglitazone instead of the racemic mixture may result in higher levels of brain exposure to pioglitazone, thus potentially improving the development of pioglitazone treatment of AD.


Asunto(s)
Subfamilia B de Transportador de Casetes de Unión a ATP/metabolismo , Encéfalo/metabolismo , Tiazolidinedionas/farmacocinética , Subfamilia B de Transportador de Casetes de Unión a ATP/química , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2 , Transportadoras de Casetes de Unión a ATP/metabolismo , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/metabolismo , Precursor de Proteína beta-Amiloide/metabolismo , Animales , Transporte Biológico , Línea Celular , Cromatografía Líquida de Alta Presión , Modelos Animales de Enfermedad , Masculino , Ratones , PPAR gamma/agonistas , Pioglitazona , Espectrometría de Masas en Tándem , Tiazolidinedionas/uso terapéutico , Distribución Tisular
3.
J Alzheimers Dis ; 44(1): 215-31, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25201780

RESUMEN

In this study, we performed gas chromatography time-of-flight mass spectrometry (GC-TOFMS)-based extracellular metabolic profiling on AßPP-transfected CHO cells (CHO-AßPP695) and its wildtype. Orthogonal partial least squares discriminant analysis (OPLS-DA) was then used to identify discriminant metabolites, which gave clues on the effects of AßPP transgene on cellular processes. To confirm the hypotheses generated based on the metabolic data, we performed biochemical assays to gather further evidence to support our findings. The OPLS-DA showed a robust differentiation following 24 h of incubation (Q2(cum) = 0.884) and 15 discriminant metabolites were identified. In contrast, extracellular Aß42 was identified to increase significantly in CHO-AßPP695 only after incubation for 48 h. The observed 24-h metabolic fluxes were associated with increased mitochondrial AßPP and reduced mitochondrial viabilities, which occurred before extracellular Aß accumulation. We also investigated the therapeutic potential of peroxisome proliferator-activated receptor gamma (PPARγ) agonists, namely rosiglitazone (RSG) and pioglitazone (PIO), by employing the same approach to characterize the metabolic profiles of CHO-AßPP695 treated with RSG and PIO, with or without their respective receptor blockers. Treatment with PIO was found to reduce the perturbation of the discriminant metabolites in CHO-AßPP695 to a larger extent than treatment with RSG. We also attributed the PIO effects on the lowering of Aß42, and restoration of mitochondrial activity to PPARγ and PPARα agonism, respectively. Taken together, PIO was demonstrated to be therapeutically superior to RSG. Our findings provide further insights into early disease stages in this AßPP model, and support the advancement of PIO in AD therapy.


Asunto(s)
Precursor de Proteína beta-Amiloide/metabolismo , PPAR alfa/agonistas , PPAR gamma/agonistas , Tiazolidinedionas/farmacología , Péptidos beta-Amiloides , Precursor de Proteína beta-Amiloide/genética , Animales , Células CHO , Diferenciación Celular , Proliferación Celular/efectos de los fármacos , Cricetulus , Análisis Discriminante , Líquido Extracelular/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/genética , Glucosa/metabolismo , Humanos , Ratones , Análisis Multivariante , Fragmentos de Péptidos , Pioglitazona , Rosiglitazona , Factores de Tiempo , Transfección
4.
PLoS One ; 9(8): e104621, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25098597

RESUMEN

Findings from epidemiology, preclinical and clinical studies indicate that consumption of coffee could have beneficial effects against dementia and Alzheimer's disease (AD). The benefits appear to come from caffeinated coffee, but not decaffeinated coffee or pure caffeine itself. Therefore, the objective of this study was to use metabolomics approach to delineate the discriminant metabolites between caffeinated and decaffeinated coffee, which could have contributed to the observed therapeutic benefits. Gas chromatography time-of-flight mass spectrometry (GC-TOF-MS)-based metabolomics approach was employed to characterize the metabolic differences between caffeinated and decaffeinated coffee. Orthogonal partial least squares discriminant analysis (OPLS-DA) showed distinct separation between the two types of coffee (cumulative Q(2) = 0.998). A total of 69 discriminant metabolites were identified based on the OPLS-DA model, with 37 and 32 metabolites detected to be higher in caffeinated and decaffeinated coffee, respectively. These metabolites include several benzoate and cinnamate-derived phenolic compounds, organic acids, sugar, fatty acids, and amino acids. Our study successfully established GC-TOF-MS based metabolomics approach as a highly robust tool in discriminant analysis between caffeinated and decaffeinated coffee samples. Discriminant metabolites identified in this study are biologically relevant and provide valuable insights into therapeutic research of coffee against AD. Our data also hint at possible involvement of gut microbial metabolism to enhance therapeutic potential of coffee components, which represents an interesting area for future research.


Asunto(s)
Enfermedad de Alzheimer , Café/química , Análisis de los Alimentos , Cromatografía de Gases y Espectrometría de Masas , Metabolómica , Humanos
5.
Int J Nanomedicine ; 7: 651-61, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22334787

RESUMEN

BACKGROUND: Realizing the therapeutic benefits of quercetin is mostly hampered by its low water solubility and poor absorption. In light of the advantages of nanovehicles in the delivery of flavanoids, we aimed to deliver quercetin perorally with nanomicelles made from the diblock copolymer, polyethylene glycol (PEG)-derivatized phosphatidylethanolamine (PE). METHODS: Quercetin-loaded nanomicelles were prepared by using the film casting method, and were evaluated in terms of drug incorporation efficiency, micelle size, interaction with Caco-2 cells, and anticancer activity in the A549 lung cancer cell line and murine xenograft model. RESULTS: The incorporation efficiency into the nanomicelles was ≥88.9% when the content of quercetin was up to 4% w/w, with sizes of 15.4-18.5 nm and polydispersity indices of <0.250. Solubilization of quercetin by the nanomicelles increased its aqueous concentration by 110-fold. The quercetin nanomicelles were stable when tested in simulated gastric (pH 1.2) and intestinal (pH 7.4) fluids, and were non-toxic to the Caco-2 cells as reflected by reversible reduction in transepithelial electrical resistance and ≤25% lactose dehydrogenase release. The anticancer activity of quercetin could be significantly improved over the free drug through the nanomicellar formulation when tested using the A549 cancer cell line and murine xenograft model. The nanomicellar quercetin formulation was well tolerated by the tumor-bearing animals, with no significant weight loss observed at the end of the 10-week study period. CONCLUSION: A stable PEG-PE nanomicellar formulation of quercetin was developed with enhanced peroral anticancer activity and no apparent toxicity to the intestinal epithelium.


Asunto(s)
Antineoplásicos/administración & dosificación , Neoplasias Pulmonares/tratamiento farmacológico , Micelas , Nanopartículas/química , Quercetina/administración & dosificación , Quercetina/química , Administración Oral , Análisis de Varianza , Animales , Antineoplásicos/química , Antioxidantes/administración & dosificación , Antioxidantes/química , Células CACO-2 , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/química , Estabilidad de Medicamentos , Femenino , Humanos , Concentración de Iones de Hidrógeno , Neoplasias Pulmonares/patología , Ratones , Nanopartículas/administración & dosificación , Tamaño de la Partícula , Fosfatidiletanolaminas/administración & dosificación , Fosfatidiletanolaminas/química , Polietilenglicoles/administración & dosificación , Polietilenglicoles/química , Ensayos Antitumor por Modelo de Xenoinjerto
6.
J Proteome Res ; 10(4): 2079-87, 2011 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-21355552

RESUMEN

3-Nitropropionic acid (3-NP), a potent irreversible inhibitor of mitochondrial complex II enzyme, leads to mitochondrial dysfunction and oxidative stress in Huntington's disease (HD) rat model. In this study, biochemical assays were used to demonstrate the presence of oxidative stress and mitochondrial dysfunction in 3-NP early stage HD rat models. Gas chromatography time-of-flight mass spectrometry (GC/TOFMS) was applied to analyze metabolites in brain and plasma of 3-NP-treated and vehicle-dosed rats. The orthogonal partial least-squares discriminant analysis (OPLS-DA) model generated using brain metabolic profiles robustly differentiated the 3-NP early stage HD rat model from the control. Metabonomic characterization of the 3-NP HD rat model facilitated the detection of biomarkers that define the physiopathological phenotype of early stage HD and elucidated the treatment effect of galantamine. Brain marker metabolites that were identified based on the OPLS-DA model were associated with altered glutathione metabolism, oxidative stress, and impaired energy metabolism. The treatment effect of galantamine in early stage HD could not be concluded mechanistically using the brain metabotype. Our study confirmed that GC/TOFMS is a strategic and complementary platform for the metabonomic characterization of 3-NP induced neurotoxicity in the early stage HD rat model.


Asunto(s)
Cromatografía de Gases y Espectrometría de Masas/métodos , Enfermedad de Huntington/inducido químicamente , Enfermedad de Huntington/metabolismo , Metaboloma , Metabolómica/métodos , Nitrocompuestos/toxicidad , Propionatos/toxicidad , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/patología , Encéfalo/fisiología , Modelos Animales de Enfermedad , Complejo II de Transporte de Electrones/antagonistas & inhibidores , Galantamina/farmacología , Enfermedad de Huntington/patología , Enfermedad de Huntington/fisiopatología , Mitocondrias/metabolismo , Nootrópicos/farmacología , Estrés Oxidativo , Ratas , Ratas Sprague-Dawley
7.
Environ Geochem Health ; 30(3): 291-303, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17874279

RESUMEN

In 2004, airborne particulate matter (PM) was collected for several aerosol episodes occurring in the southern region of Taiwan. The particulate samples were taken using both a MOUDI (Micro-orifice Uniform Deposit Impactor) and a nano-MOUDI sampler. These particulate samples were analyzed for major water-soluble ionic species with an emphasis to characterize the mass concentrations and distributions of these ions in the ambient ultrafine (PM0.1, diameter <0.1 microm) and nano mode (PMnano, diameter <0.056 microm) particles. Particles collected at the sampling site (the Da-Liao station) on the whole exhibited a typical tri-modal size distribution on mass concentration. The mass concentration ratios of PMnano/PM2.5, PM0.1/PM2.5, and PM1/PM2.5 on average were 1.8, 2.9, and 71.0%, respectively. The peak mass concentration appeared in the submicron particle mode (0.1 microm < diameter <1.0 microm). Mass fractions (percentages) of the three major water-soluble ions (nitrate, sulfate, and ammonium) as a group in PMnano, PM0.1, PM1, and PM2.5 were 18.4, 21.7, 50.0, and 50.7%, respectively. Overall, results from this study supported the notion that secondary aerosols played a significant role in the formation of ambient submicron particulates (PM0.1-1). Particles smaller than 0.1 microm were essentially basic, whereas those greater than 2.5 microm were neutral or slightly acidic. The neutralization ratio (NR) was close to unity for airborne particles with diameters ranging from 0.18 to 1 microm. The NRs of these airborne particles were found strongly correlated with their sizes, at least for samples taken during the aerosol episodes under study. Insofar as this study is exploratory in nature, as only a small number of particulate samples were used, there appears to be a need for further research into the chemical composition, source contribution, and formation of the nano and ultrafine mode airborne particulates.


Asunto(s)
Nanopartículas/química , Material Particulado/química , Aniones/análisis , Aniones/química , Cationes/análisis , Cationes/química , Monitoreo del Ambiente , Humanos , Compuestos Inorgánicos/química , Taiwán
8.
J Air Waste Manag Assoc ; 55(4): 502-9, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15887893

RESUMEN

Concentrations and distributions of three major water-soluble ion species (sulfate, nitrate, and ammonium) contained in ambient particles were measured at three sampling sites in the Kao-ping ambient air quality basin, Taiwan. Ambient particulate matter (PM) samples were collected in a Micro-orifice Uniform Deposit Impactor from February to July 2003 and were analyzed for water-soluble ion species with an ion chromatograph. The PM1/ PM2.5 and PM1/PM10 concentration ratios at the emission source site were 0.73 and 0.53 and were higher than those (0.68 and 0.48) at the background site because there are more combustion sources (i.e., industrial boilers and traffic) around the emission source site. Mass-size distributions of PM NO3- were found in both the fine and coarse modes. SO4(2-)and NH4+ were found in the fine particle mode (PM2.5), with significant fractions of submicron particles (PM1). The source site had higher PM1/PM10(79, 42, and 90%) and PM1/PM2.5 concentration ratios (90, 58, and 93%) for the three major inorganic secondary aerosol components (SO4(2-), NO3-, and NH4+) than the receptor site (65, 27, and 65% for PM1/PM10, 69, 51, and 70% for PM1/PM2.5. Results obtained in this study indicate that the PM1 (submicron aerosol particles) fraction plays an important role in the ambient atmosphere at both emission source and receptor sites. Further studies regarding the origin and formation of ambient secondary aerosols are planned.


Asunto(s)
Contaminantes Atmosféricos/análisis , Nitratos/análisis , Sulfatos/análisis , Monitoreo del Ambiente , Tamaño de la Partícula , Taiwán
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...